HOWL Stock Analysis: Buy, Sell, or Hold?
HOWL - Werewolf Therapeutics, Inc. Common Stock
$1.01
0.05 (5.38%)
▲
5d:
+17.02%
30d:
+64.9%
90d:
+59.43%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Mar 31, 2026
0d
Get Alerted When HOWL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HOWL is 16.1% above fair value ($0.87). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HOWL is 16.1% above fair value ($0.87). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: HOWL is currently trading at $1.01, which is considered extended relative to its 30-day fair value range of $0.64 to $0.87.
Technical Outlook: Technically, HOWL is in a downtrend. The price is approaching resistance at $1.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: HOWL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+630.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOWL is in a downtrend. The price is approaching resistance at $1.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: HOWL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+630.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.64 -
$0.87
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+16.1% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 630.4% below Wall St target ($7.00)
- WARNING: Recommendation downgraded due to 16.1% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.64 -
$0.87
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.75
Resistance Level
$1.03
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.97
Wall Street Target
$7.00
(+630.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 02, 2026 4:52 PM ET
Data refreshes hourly during market hours. Next update: 5:52 PM
Data refreshes hourly during market hours. Next update: 5:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOWL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Luke Evnin
SELL
38782 shares
2026-01-16
Luke Evnin
SELL
37413 shares
2026-01-15
Luke Evnin
SELL
30616 shares
2026-01-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
